ATE401898T1 - Phosphatidyl-l-serin und phosphatidylsäure zur behandlung von depression und stresszuständen - Google Patents

Phosphatidyl-l-serin und phosphatidylsäure zur behandlung von depression und stresszuständen

Info

Publication number: ATE401898T1
Authority: AT; Austria
Prior art keywords: serine; phosphatidic acid; lecithin; phosphatidyl; phosphatidy
Prior art date: 2000-10-23

Application number

AT01114833T

Other languages

English (en)

Inventor

David Rutenberg

Original Assignee

Lipogen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-23

Filing date

2001-06-28

Publication date

2008-08-15

2001-06-28 Application filed by Lipogen Ltd filed Critical Lipogen Ltd

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE401898T1 publication Critical patent/ATE401898T1/de

Links

208000020401 Depressive disease Diseases 0.000 title 1
239000002253 acid Substances 0.000 title 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 abstract 5
229960001153 serine Drugs 0.000 abstract 5
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 3
229940067606 lecithin Drugs 0.000 abstract 3
235000010445 lecithin Nutrition 0.000 abstract 3
239000000787 lecithin Substances 0.000 abstract 3
230000002996 emotional effect Effects 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
230000003340 mental effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000003904 phospholipids Chemical class 0.000 abstract 2
239000002994 raw material Substances 0.000 abstract 2
JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 abstract 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract 1
240000002791 Brassica napus Species 0.000 abstract 1
235000004977 Brassica sinapistrum Nutrition 0.000 abstract 1
102000011420 Phospholipase D Human genes 0.000 abstract 1
108090000553 Phospholipase D Proteins 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
125000005313 fatty acid group Chemical group 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
230000036651 mood Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000000697 serotonin reuptake Effects 0.000 abstract 1
229940083466 soybean lecithin Drugs 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Polymers & Plastics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nutrition Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01114833T 2000-10-23 2001-06-28 Phosphatidyl-l-serin und phosphatidylsäure zur behandlung von depression und stresszuständen ATE401898T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL139224A IL139224A (en)	2000-10-23	2000-10-23	Anti depressant, stress suppressor and mood improver

Publications (1)

Publication Number	Publication Date
ATE401898T1 true ATE401898T1 (de)	2008-08-15

Family

ID=11074750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01114833T ATE401898T1 (de)	2000-10-23	2001-06-28	Phosphatidyl-l-serin und phosphatidylsäure zur behandlung von depression und stresszuständen

Country Status (10)

Country	Link
US (1)	US6410522B1 (de)
EP (1)	EP1201244B1 (de)
AT (1)	ATE401898T1 (de)
CA (1)	CA2352528C (de)
DE (1)	DE60134931D1 (de)
DK (1)	DK1201244T3 (de)
ES (1)	ES2309021T3 (de)
HK (1)	HK1046237B (de)
IL (1)	IL139224A (de)
PT (1)	PT1201244E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8178150B2 (en)	2000-02-22	2012-05-15	Suzanne Jaffe Stillman	Water containing soluble fiber
US7892586B2 (en)	2001-02-22	2011-02-22	Suzanne Jaffe Stillman	Water containing soluble fiber
US7115297B2 (en)	2000-02-22	2006-10-03	Suzanne Jaffe Stillman	Nutritionally fortified liquid composition with added value delivery systems/elements/additives
WO2001068104A1 (en) *	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Compounds for the treatment of psychiatric or substance abuse disorders
US20050129738A1 (en) *	2002-06-16	2005-06-16	Lipogen Ltd.	Infant formula supplemented with phospholipids
IL150240A (en) *	2002-06-16	2005-07-25	Lipogen Ltd	Infant formula supplemented with phospholipids
US6878532B1 (en)	2003-04-28	2005-04-12	Sioux Biochemical, Inc.	Method of producing phosphatidylserine
WO2005044176A2 (en) *	2003-11-10	2005-05-19	Lipogen Ltd.	Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
GB0400031D0 (en)	2004-01-03	2004-02-04	Univ Sheffield	Depression treatment
EP1765075A4 (de) *	2004-06-10	2010-11-10	Mclean Hospital Corp	Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US20090215714A1 (en) *	2004-06-10	2009-08-27	Perry Renshaw	Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7947661B2 (en) *	2004-08-11	2011-05-24	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
EP1896074A4 (de) *	2005-05-25	2009-04-22	Liponex Inc	Pharmazeutische zusammensetzungen zur behandlung oder prävention von koronararterienkrankheit
IL182372A0 (en) *	2007-04-01	2008-01-20	Enzymotec Ltd	Compositions containing phosphatidylserine in treating diabetes-associated conditions
US8846338B2 (en)	2008-08-07	2014-09-30	Lipogen Ltd.	Processes for the preparation of phosphatides
US8546104B2 (en)	2008-08-07	2013-10-01	Lipogen Ltd.	Processes for the preparation of phosphatide salts
US20100041621A1 (en) *	2008-08-15	2010-02-18	Perry Renshaw	Methods and compositions for improving cognitive performance
US9326961B2 (en) *	2010-02-26	2016-05-03	Coape, Ltd	Diet and methods for improving learning capacity, mood and behavior in mammals
US20130064803A1 (en) *	2011-09-14	2013-03-14	Naidu Lp	BIO-REPLENISHMENT (BioRep) FOR COGNITIVE HEALTH
EP2769725B1 (de) *	2013-02-22	2016-06-29	Lipogen Ltd.	Zusammensetzungen zur Linderung von Symptomen im Zusammenhang mit dem prämenstruellen Syndrom und prämenstrueller Dysphoriestörung
EP2881104A1 (de)	2013-12-05	2015-06-10	Lonza Ltd	Verwendung von Zusammensetzungen mit Phosphatidylserin und Phosphatidsäure und/oder Salzen davon zur Verringerung oder Vorbeugung von Schwitzen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4117629A1 (de) *	1991-05-29	1992-12-03	Max Planck Gesellschaft	Phospatidylserine
US5700668A (en) *	1995-12-08	1997-12-23	Italfarmaco Sud S.P.A.	Process for the industrial preparation of phosphatidylserine
IL118180A (en) *	1996-05-08	2000-12-06	Modus Biolog Membranes Ltd	Pharmaceutical compositions comprising a phosphatidic acid (PA) enriched natural phospholipid preparation and the production of such preparation

2000
- 2000-10-23 IL IL139224A patent/IL139224A/en active IP Right Grant
2001
- 2001-06-28 ES ES01114833T patent/ES2309021T3/es not_active Expired - Lifetime
- 2001-06-28 DK DK01114833T patent/DK1201244T3/da active
- 2001-06-28 EP EP01114833A patent/EP1201244B1/de not_active Expired - Lifetime
- 2001-06-28 PT PT01114833T patent/PT1201244E/pt unknown
- 2001-06-28 DE DE60134931T patent/DE60134931D1/de not_active Expired - Lifetime
- 2001-06-28 AT AT01114833T patent/ATE401898T1/de active
- 2001-07-03 US US09/897,034 patent/US6410522B1/en not_active Expired - Lifetime
- 2001-07-06 CA CA002352528A patent/CA2352528C/en not_active Expired - Fee Related
2002
- 2002-10-15 HK HK02107472.0A patent/HK1046237B/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2309021T3 (es)	2008-12-16
US6410522B1 (en)	2002-06-25
HK1046237B (en)	2009-04-09
HK1046237A1 (en)	2003-01-03
DK1201244T3 (da)	2008-11-17
IL139224A (en)	2009-09-01
CA2352528C (en)	2005-12-06
US20020072508A1 (en)	2002-06-13
CA2352528A1 (en)	2002-04-23
PT1201244E (pt)	2008-09-23
EP1201244A3 (de)	2003-12-10
DE60134931D1 (de)	2008-09-04
EP1201244A2 (de)	2002-05-02
EP1201244B1 (de)	2008-07-23

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1201244

Country of ref document: EP

Publication	Publication Date	Title
ATE401898T1 (de)	2008-08-15	Phosphatidyl-l-serin und phosphatidylsäure zur behandlung von depression und stresszuständen
BRPI0512864B8 (pt)	2021-05-25	composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
CA2162232A1 (en)	1996-05-09	Cerebration improver
BR0009001A (pt)	2002-01-02	Processo para a produção de queijo, uso de um queijo, e de uma fosfolipase, e, queijo
ATE462427T1 (de)	2010-04-15	Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE492279T1 (de)	2011-01-15	Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE556697T1 (de)	2012-05-15	Kosmetische zusammensetzung enthaltend eine flüchtige fettphase
NO20076382L (no)	2008-02-08	Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
UA88633C2 (ru)	2009-11-10	Структурированная композиция на основе липидов, способ ее изготовления и способ снижения атерогенного риска человека
ATE514345T1 (de)	2011-07-15	Zusammensetzung zur senkung des blutcholesterolspiegels
NO20003693L (no)	2000-09-20	Beroligende feromoner for svin for Õ minske stress, angst og aggressivitet
ATE431133T1 (de)	2009-05-15	Präparat zur verhinderung und/oder behandlung von demenz syndromen
EA200602191A1 (ru)	2007-06-29	5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BR9815832A (pt)	2001-03-20	Composição de proteìna vegetal contendo um material de proteìna vegetal exaurido de isoflavona com um material contendo isoflavona
DE60044152D1 (de)	2010-05-20	Bupropion Metaboliten zur Behandlung von Angstzuständen
BR0317888A (pt)	2005-12-06	Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
ATE42776T1 (de)	1989-05-15	Acrylfasern zur herstellung von kohlenstoffasern.
BRPI0502377A (pt)	2006-02-21	método para tratar plantas ou partes de plantas
BR0112919A (pt)	2003-07-01	Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
ATE492618T1 (de)	2011-01-15	Herstellung von speiseöl mit hohem diglyceridgehalt
ATE397058T1 (de)	2008-06-15	In vitro rekonstituierte lagen des menschlichen hornhautepithels und verfahren zur herstellung davon
DE59002572D1 (de)	1993-10-07	Omega-3-fettsäurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
DE50207740D1 (de)	2006-09-14	Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs)
ATE384446T1 (de)	2008-02-15	PHARMAZEUTISCHE- UND NAHRUNGSMITTELZUSAMMENZETZUNGEN MIT ßHOLZALKOHOLß UND ßHOLZSTEROLß ZUR SENKUNG DES SERUMCHOLESTERINS
WO2004047727A3 (en)	2005-05-06	Compositions and methods for diagnosing and treating mood disorders